Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the target of a large drop in short interest during the month of February. As of February 13th, there was short interest totaling 24 shares, a drop of 96.7% from the January 29th total of 725 shares. Based on an average daily volume of 2,057 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are sold short. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 2,057 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of large investors have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at $391,000. Tema Etfs LLC bought a new stake in Ascentage Pharma Group International during the second quarter worth about $610,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Ascentage Pharma Group International during the third quarter worth about $96,000. ABC Arbitrage SA acquired a new stake in Ascentage Pharma Group International during the third quarter worth about $204,000. Finally, UBS Group AG increased its holdings in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the period.

Ascentage Pharma Group International Trading Up 0.2%

NASDAQ AAPG opened at $25.05 on Thursday. The firm has a 50-day moving average price of $25.94 and a two-hundred day moving average price of $32.84. Ascentage Pharma Group International has a 12-month low of $17.56 and a 12-month high of $48.45. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Piper Sandler assumed coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, November 5th. They issued an “overweight” rating and a $48.00 price target on the stock. Oppenheimer assumed coverage on shares of Ascentage Pharma Group International in a report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price target on the stock. Rodman & Renshaw began coverage on Ascentage Pharma Group International in a report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price objective for the company. Finally, Truist Financial set a $51.00 target price on Ascentage Pharma Group International in a research report on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $48.40.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.